Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports

Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but serious pathology associated with the use of bisphosphonates (BPs) and antiresorptive drugs in patients with bone metastases, multiple myeloma and osteoporosis. Various cases of patients with jaw bone necrosis due to BPs ha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mihaylova Z., Ugrinov R., Aleksiev E., Stanimirov P.
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2019
Materias:	mronj bisphosphonates anti-angiogenic drugs sunitinib chemotherapy Medicine R
Acceso en línea:	https://doaj.org/article/107e0ef6c84540ddbe2f2576f9014dfa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:107e0ef6c84540ddbe2f2576f9014dfa
record_format	dspace
spelling	oai:doaj.org-article:107e0ef6c84540ddbe2f2576f9014dfa2021-12-02T19:11:31ZOsteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports0324-175010.2478/amb-2019-0019https://doaj.org/article/107e0ef6c84540ddbe2f2576f9014dfa2019-05-01T00:00:00Zhttps://doi.org/10.2478/amb-2019-0019https://doaj.org/toc/0324-1750Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but serious pathology associated with the use of bisphosphonates (BPs) and antiresorptive drugs in patients with bone metastases, multiple myeloma and osteoporosis. Various cases of patients with jaw bone necrosis due to BPs have recently been reported in the literature. Anti-angiogenic drugs are novel anticancer agents prescribed to patients with renal carcinoma, lung carcinoma, soft tissue metastases, etc. Anti-angiogenic drugs target the vascular endothelial growth factor’s (VEGF) signaling pathways via different mechanisms and thus inhibit tumor cell proliferation, neoangiogenesis and tumor growth. Several reports have suggested a higher incidence of MRONJ in patients treated with BPs in combination with anti-angiogenic drugs. However, there is currently no sufficient data in the literature about the risk of ONJ in patients taking anti-angiogenic drugs or cancer chemotherapy alone. We present two clinical cases of osteonecrosis of the jaw in patients treated with chemotherapy, but no history of BPs. In the first case the necrosis is related to the anti-angiogenic agent sunitinib in a patient with lung metastases and in the second case- to complex chemotherapy in a patient with acute myeloid leukemia. We recommend conservative treatment with antibiotics in both cases, together with antiseptics and surgical removal of the necrotic bone following total demarcation of the sequesters.Mihaylova Z.Ugrinov R.Aleksiev E.Stanimirov P.Sciendoarticlemronjbisphosphonatesanti-angiogenic drugssunitinibchemotherapyMedicineRENActa Medica Bulgarica, Vol 46, Iss 2, Pp 51-56 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	mronj bisphosphonates anti-angiogenic drugs sunitinib chemotherapy Medicine R
spellingShingle	mronj bisphosphonates anti-angiogenic drugs sunitinib chemotherapy Medicine R Mihaylova Z. Ugrinov R. Aleksiev E. Stanimirov P. Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
description	Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but serious pathology associated with the use of bisphosphonates (BPs) and antiresorptive drugs in patients with bone metastases, multiple myeloma and osteoporosis. Various cases of patients with jaw bone necrosis due to BPs have recently been reported in the literature. Anti-angiogenic drugs are novel anticancer agents prescribed to patients with renal carcinoma, lung carcinoma, soft tissue metastases, etc. Anti-angiogenic drugs target the vascular endothelial growth factor’s (VEGF) signaling pathways via different mechanisms and thus inhibit tumor cell proliferation, neoangiogenesis and tumor growth. Several reports have suggested a higher incidence of MRONJ in patients treated with BPs in combination with anti-angiogenic drugs. However, there is currently no sufficient data in the literature about the risk of ONJ in patients taking anti-angiogenic drugs or cancer chemotherapy alone. We present two clinical cases of osteonecrosis of the jaw in patients treated with chemotherapy, but no history of BPs. In the first case the necrosis is related to the anti-angiogenic agent sunitinib in a patient with lung metastases and in the second case- to complex chemotherapy in a patient with acute myeloid leukemia. We recommend conservative treatment with antibiotics in both cases, together with antiseptics and surgical removal of the necrotic bone following total demarcation of the sequesters.
format	article
author	Mihaylova Z. Ugrinov R. Aleksiev E. Stanimirov P.
author_facet	Mihaylova Z. Ugrinov R. Aleksiev E. Stanimirov P.
author_sort	Mihaylova Z.
title	Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
title_short	Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
title_full	Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
title_fullStr	Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
title_full_unstemmed	Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
title_sort	osteonecrosis of the jaws in patients receiving anti-angiogenic drugs and chemotherapeutics: literature review and case reports
publisher	Sciendo
publishDate	2019
url	https://doaj.org/article/107e0ef6c84540ddbe2f2576f9014dfa
work_keys_str_mv	AT mihaylovaz osteonecrosisofthejawsinpatientsreceivingantiangiogenicdrugsandchemotherapeuticsliteraturereviewandcasereports AT ugrinovr osteonecrosisofthejawsinpatientsreceivingantiangiogenicdrugsandchemotherapeuticsliteraturereviewandcasereports AT aleksieve osteonecrosisofthejawsinpatientsreceivingantiangiogenicdrugsandchemotherapeuticsliteraturereviewandcasereports AT stanimirovp osteonecrosisofthejawsinpatientsreceivingantiangiogenicdrugsandchemotherapeuticsliteraturereviewandcasereports
_version_	1718377072416522240

Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports

Ejemplares similares